

BACKGROUND INFORMATION

Lantheus-ANSTO agreement

About Lantheus Medical Imaging, Inc.

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medicine for the past 50 years, is committed to advancing and investing in the field of diagnostic imaging. The company's proven success in discovering, developing and marketing innovative medical imaging agents provides a solid platform from which to bring forward breakthrough new tools for the diagnosis and management of disease. The company is home to leading cardiac imaging brands, including Cardiolite[®] (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), DEFINITY[®] Vial For (Perflutren Lipid Microsphere) Injectable Suspension, and TechneLite[®] (Technetium Tc99m Generator) and has nearly 600 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada, and Australia. For more information, visit www.lantheus.com.

About the Australian Nuclear Science and Technology Organisation (ANSTO)

The Australian Nuclear Science and Technology Organisation (ANSTO) is Australia's only nuclear research facility and the center of Australia's nuclear expertise, specializing in the applications of nuclear science. ANSTO provides a broad range of radiopharmaceuticals and radiochemicals for the Australian and New Zealand markets. ANSTO also offers insight into and expertise on global nuclear issues, on which it provides advice to the Australian Federal Government, and contributes to programs to assist with radiation and nuclear safety in countries in the Asia-Pacific region. ANSTO is owned by the Australian Government. ANSTO has approximately 950 employees and is based at Lucas Heights, about 40 minutes south of Sydney, on a secure campus of 70 hectares. For more information on ANSTO's radiopharmaceutical production, please visit www.ansto.gov.au/commercial_services/health/ari/ansto_radiopharmaceuticals. For more information on ANSTO generally, please visit www.ansto.gov.au

About LEU- based Mo-99

Mo-99 is the parent isotope of technetium-99m (Tc-99m), the most widely used medical radioisotope in the world for molecular and nuclear diagnostic imaging procedures. Mo-99 is produced by the irradiation of uranium "targets" in a reactor. There are only few major worldwide suppliers of Mo-99, and most use highly-enriched uranium (HEU) targets. A primary objective of the National Nuclear Security Administration's Global Threat Reduction Initiative (GTRI) is to minimize proliferation risks by phasing out the use of HEU in civil commerce. ANSTO is the only global commercial supplier that currently produces Mo-99 using LEU targets, and Lantheus will be the first generator manufacturer to bring this LEU-based Mo-99 to the U.S. market.

About Technetium-99m and TechneLite[®]

Technetium-99m (Tc99m), which is the decay product of molybdenum-99 (Mo-99), is the most commonly used medical radioisotope in the world, comprising approximately 80 percent of all nuclear medicine procedures. Tc99m is used in Lantheus Medical Imaging's TechneLite[®] (Technetium Tc99m Generator) generators which are distributed to hospitals and radiopharmacies as a source of Tc99m for diagnostic imaging procedures. Tc99m is also used with Cardiolite[®] (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), one of the world's most widely-used cardiac imaging agents and the only technetium labeled myocardial perfusion agent that has been used to image more than 40 million patients. In diagnostic use, the Tc99m is attached to a specific molecule and injected into the patient. The diagnostic medicine then travels to the site or organ of interest, and a special camera is used to pick up the gamma rays emitted from the radioactive material in the body and create images for diagnostic evaluation.

For more information contact Media and Community Relations Manager Sharon Kelly on (02) 9717 9575 or 0400 394 085